Targeted treatments for lung cancer

Description: In this course I describe the faulty genes, pathways and proteins that drive small cell and non-small cell lung cancer. I also explain the scientific rationale behind targeted treatments in use and in development for these diseases, such as EGFR inhibitors, ALK and ROS1 inhibitors, B-Raf inhibitors, angiogenesis inhibitors and immunotherapy with checkpoint inhibitors.
Level: Intermediate/Advanced
Audience: Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
Cost: TBC
To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
View an outline of the programme